Eosinophilic esophagitis: Pathogenesis, genetics, and therapy - 18/08/11
Reprint requests: Marc Rothenberg, MD, PhD, Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229.Cincinnati, Ohio
Abstract |
Eosinophilic esophagitis (EE) is a recently recognized disorder characterized by the accumulation of eosinophils in the esophagus. Symptoms of EE frequently mimic those of gastroesophageal reflux disease, but the 2 diseases are quite distinct in terms of the histopathology and response to therapy. We demonstrate that EE involves the interplay of numerous genes, especially the eosinophil chemoattractant eotaxin-3, allowing molecular distinction from other forms of esophagitis and consideration of targeted therapeutic intervention.
Le texte complet de cet article est disponible en PDF.Key words : Eosinophilic esophagitis, eosinophils, eosinophil-associated gastrointestinal disorder, allergy, eotaxin
Abbreviations used : CE, CLC, EE, GERD, hpf, SNP
Plan
| Supported in part by the Burroughs Wellcome Fund (M.E.R), National Institutes of Health grants R01 AI45898 (M.E.R.) and R21 DK074626-01 (N.W.), the CURED (Campaign Urging Research for Eosinophilic Disease) Foundation, and the Food Allergy and Anaphylaxis Network (M.E.R.). Disclosure of potential conflict of interest: M. E. Rothenberg has consultant arrangements with GlaxoSmithKline, Ception Therapeutics, Cambridge Antibody Technology, and MedaCorp; owns stock in Ception Therapeutics; has received grant support from Cambridge Antibody Technology; is on the speakers’ bureau for Merck; and has received honorarium from GlaxoSmithKline, Ception Therapeutics, Merck, and Tanox. The rest of the authors have declared that they have no conflict of interest. |
Vol 118 - N° 5
P. 1054-1059 - novembre 2006 Retour au numéro
Article précédent
- Determinants of future long-term asthma control
- Michael Schatz, Robert S. Zeiger, William M. Vollmer, David Mosen, E. Francis Cook
- Initial Fc
RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation - Bernhard F. Gibbs, Anne Räthling, Detlef Zillikens, Michael Huber, Helmut Haas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?